{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:46:39Z","timestamp":1764510399110,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1379,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Institutional","award":["P30 CA082709"],"award-info":[{"award-number":["P30 CA082709"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.bbmt.2010.10.016","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T07:27:07Z","timestamp":1289374027000},"page":"987-994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Primary Refractory and Relapsed and Refractory Non-Hodgkin Lymphoma"],"prefix":"10.1016","volume":"17","author":[{"given":"Shivani","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa L.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Robert P.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angie","family":"Secrest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Baute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif S.","family":"Farag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2010.10.016_bib1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJM199403243301206","article-title":"Bone marrow transplantation","volume":"330","author":"Armitage","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.10.016_bib2","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin\u2019s lymphoma","volume":"316","author":"Philip","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.10.016_bib3","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/sj.bmt.1702433","article-title":"Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin\u2019s lymphoma","volume":"25","author":"Copelan","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.016_bib4","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/10428190500158466","article-title":"Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin\u2019s lymphoma","volume":"46","author":"Robertson","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.10.016_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1083-8791(03)00205-2","article-title":"The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial","volume":"9","author":"Stiff","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.016_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/1097-0142(19890115)63:2<228::AID-CNCR2820630204>3.0.CO;2-3","article-title":"High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies","volume":"63","author":"Collins","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2010.10.016_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0014-2964(76)90239-5","article-title":"Combination chemotherapy with\u00a04\u2019Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia","volume":"12","author":"Dombernowsky","year":"1976","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bbmt.2010.10.016_bib8","first-page":"119","article-title":"Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors","volume":"47","author":"Chang","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.10.016_bib9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJM198503143121106","article-title":"Etoposide (VP-16-213). Current status of an active anticancer drug","volume":"312","author":"O\u2019Dwyer","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2010.10.016_bib10","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10428190500527769","article-title":"Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation","volume":"47","author":"Puig","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.10.016_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.bmt.1701334","article-title":"Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan\/cyclophosphamide vs total body irradiation: a meta-analysis","volume":"22","author":"Hartman","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.10.016_bib12","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V83.12.3780.3780","article-title":"Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy","volume":"83","author":"Miller","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.016_bib13","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.1994.12.12.2535","article-title":"Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma","volume":"12","author":"Stone","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.016_bib14","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.016_bib15","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.016_bib16","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2003.04.031","article-title":"Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers","volume":"21","author":"Kantarjian","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.016_bib17","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1158\/1078-0432.CCR-05-2664","article-title":"Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment","volume":"12","author":"Gandhi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.10.016_bib18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1200\/jco.2008.26.15_suppl.8564","article-title":"Phase I\/II trial of clofarabine in refractory and\/or relapsed non-Hodgkin\u2019s lymphoma (NHL)","volume":"26","author":"Nabhan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.016_bib19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/10428190902730227","article-title":"Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma","volume":"50","author":"Blum","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.10.016_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0026-895X(24)12176-1","article-title":"Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro- beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro- beta-D-ribofuranosyl)adenine in CEM cells","volume":"55","author":"Parker","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bbmt.2010.10.016_bib21","first-page":"3030","article-title":"Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine","volume":"56","author":"Xie","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2010.10.016_bib22","first-page":"3580","article-title":"DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.10.016_bib23","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","article-title":"Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression","volume":"15","author":"Montoto","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2010.10.016_bib24","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.016_bib25","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1182\/blood.V96.10.3537","article-title":"Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria","volume":"96","author":"Genini","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.016_bib26","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood.V114.22.198.198","article-title":"Phase I trial of high-dose clofarabine and busulfan as a myeloablative regimen prior to allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute leukemia","volume":"114","author":"Farag","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.10.016_bib27","doi-asserted-by":"crossref","first-page":"647s","DOI":"10.1200\/jco.2005.23.16_suppl.7109","article-title":"Clofarabine adiministration weekly to adult patients with advanced solid tumors in a phase I dose-finding study","volume":"23","author":"Cunningham","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.10.016_bib28","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/leu.2009.185","article-title":"A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia","volume":"23","author":"Hijiya","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.10.016_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ajh.21365","article-title":"The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia","volume":"84","author":"McGregor","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2010.10.016_bib30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1177\/0091270004269236","article-title":"Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia","volume":"44","author":"Bonate","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2010.10.016_bib31","first-page":"6335","article-title":"Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias","volume":"9","author":"Gandhi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.10.016_bib32","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110004544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110004544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:39:29Z","timestamp":1761057569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879110004544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1083879110004544"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.10.016","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Primary Refractory and Relapsed and Refractory Non-Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}